Tag: Heart Failure
Surprise outcome for SODIUM-HF
Sotagliflozin SCORED MACE benefit
Omecamtiv mecarbil does not impact exercise capacity of patients with HFrEF
RCT-IVVE trial: Do HF patients benefit from annual flu shots?
Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes
Left bundle branch area pacing is a feasible technique for HF and bradyarrhythmia
Focus on the efficacy of cardiac resynchronisation therapy in HF plus concomitant AF
RESET: No survival benefit of CRT-defibrillator over CRT-pacemaker in heart failure
Reduction in atrial arrhythmias in patients with CIED on SGLT2 inhibitors
Empagliflozin efficacious in HF patients with preserved ejection fractions ≥50%
EMPULSE: Empagliflozin improves outcomes of acute heart failure
CHIEF-HF: Canagliflozin improves health status in heart failure
DREAM-HF: MPC therapy for HFrEF did not meet primary endpoint
Therapeutic approaches in heart failure with diabetes
Valsartan seems to attenuate hypertrophic cardiomyopathy progression
Empagliflozin: First drug with clear benefit in HFpEF patients
CardioMEMS: neutral outcome but possible benefit prior to COVID-19
Antagonising the mineralocorticoid receptor beneficial for patients with diabetes and CKD
2021 ESC Guidelines on Heart Failure
ESC 2021 Highlights Podcast
Iron substitution improves LVEF in intensively treated CRT patients with iron deficiency
Novel mineralocorticoid receptor antagonist effective irrespective of HF history
Iron substitution in iron-deficient HF patients is highly cost-effective
Omecamtiv mecarbil might be less effective in patients with atrial fibrillation or flutter
Vericiguat effective irrespective of atrial fibrillation status
Baroreflex activation: a novel option to improve heart failure symptoms
Beta-blocker withdrawal to enhance exercise capacity in heart failure?
Inconclusive results for dapagliflozin treatment in heart failure
Computerised cognitive training improves cognitive function in HF patients
Real-world study suggests sacubitril/valsartan benefits elderly patients with HF
Proenkephalin: A useful biomarker for new-onset heart failure?
Weight loss associated with increased mortality risk in heart failure patients
Echocardiographic parameters linked to dementia diagnosis
Telemedicine: Every light has its shadow
COVID-19-related HF: from systemic infection to cardiac inflammation
Increased COVID-19 mortality in patients with cardiorenal comorbidity
Myocardial infarction outcomes were significantly affected by the pandemic
Empagliflozin linked to lower cardiovascular risk and renal events in real-world study
Efficacy of dapagliflozin and empagliflozin not influenced by diabetes status
TAPSE effective biomarker associated with high-risk of severe COVID-19
COVID-19 in AF patients with HF: no higher mortality but longer hospital stay
Psychoactive substances put young people at risk of cardiovascular disease
Heart failure patients might be at an increased risk for head and neck cancer
The challenge of improving the quality of life of heart failure patients
Trastuzumab associated with cardiotoxicity in breast cancer
PARADISE-MI: Sacubitril/valsartan not superior to ramipril in reducing HF events
Older adults with heart failure benefit from rehabilitation programme
Quality improvement intervention fails to improve care for patients with heart failure
Sacubitril/valsartan does not reduce NT-proBNP versus valsartan alone in HFrEF
Ablation-based rhythm control as effective as rate control in AF and HF
RACE 3 long-term results show fading benefit of targeted therapies in AF and HF
Omecamtiv mecarbil improves outcomes in HFrEF-patients
IV iron reduces HF hospitalisation
Dapagliflozin reduces renal risk independent of CV disease status
“Strongly consider an SGLT2-inhibitor in most T2DM patients”
Additional HFrEF education and patient-engagement tools
High-dose influenza vaccine in patients with CVD
SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients
Reduced NT-proBNP in HFpEF with sacubitril/valsartan
Antihypertensives also reduce CV risk in people with normal blood pressure
SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations
Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy
Vericiguat shows beneficial effects in a very high-risk HF population
DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
PARAGON-HF: Benefits for women and lower ejection fraction
Frequent use of beta-blocker after HFpEF hospitalisations in elderly patients without compelling indications
High 5-year survival rates for older HF patients without initial severe comorbidity
